Disease | multiple sclerosis |
Symptom | C0024312|lymphopenia |
Sentences | 1 |
PubMedID- 25361781 | Objective: to assess whether pretreatment-lymphocyte counts, treatment before fingolimod, age, sex, or body mass index (bmi) affects the risk of fingolimod-induced lymphopenia in patients with relapsing-remitting multiple sclerosis (rrms). |
Page: 1